ID   GEPH_HUMAN              Reviewed;         736 AA.
AC   Q9NQX3; Q96KU4; Q9H4E9; Q9P2G2;
DT   27-APR-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2000, sequence version 1.
DT   10-MAY-2017, entry version 163.
DE   RecName: Full=Gephyrin {ECO:0000303|PubMed:10839351};
DE   Includes:
DE     RecName: Full=Molybdopterin adenylyltransferase;
DE              Short=MPT adenylyltransferase;
DE              EC=2.7.7.75 {ECO:0000305|PubMed:26613940};
DE     AltName: Full=Domain G;
DE   Includes:
DE     RecName: Full=Molybdopterin molybdenumtransferase;
DE              Short=MPT Mo-transferase;
DE              EC=2.10.1.1 {ECO:0000305|PubMed:22040219, ECO:0000305|PubMed:26613940};
DE     AltName: Full=Domain E;
GN   Name=GPHN {ECO:0000312|HGNC:HGNC:15465}; Synonyms=GPH, KIAA1385;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Hippocampus;
RX   PubMed=10839351; DOI=10.1016/S0896-6273(00)81165-4;
RA   Butler M.H., Hayashi A., Okoshi N., Villmann C., Becker C.M., Feng G.,
RA   De Camilli P., Solimena M.;
RT   "Autoimmunity to gephyrin in Stiff-Man syndrome.";
RL   Neuron 26:307-312(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), INVOLVEMENT IN MOCODC, AND
RP   PATHWAY.
RX   PubMed=11095995; DOI=10.1086/316941;
RA   Reiss J., Gross-Hardt S., Christensen E., Schmidt P., Mendel R.R.,
RA   Schwarz G.;
RT   "A mutation in the gene for the neurotransmitter receptor-clustering
RT   protein gephyrin causes a novel form of molybdenum cofactor
RT   deficiency.";
RL   Am. J. Hum. Genet. 68:208-213(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Kidney;
RX   PubMed=11418245; DOI=10.1016/S0378-1119(01)00511-X;
RA   David-Watine B.;
RT   "The human gephyrin (GPHN) gene: structure, chromosome localization
RT   and expression in non-neuronal cells.";
RL   Gene 271:239-245(2001).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=10718198; DOI=10.1093/dnares/7.1.65;
RA   Nagase T., Kikuno R., Ishikawa K., Hirosawa M., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XVI.
RT   The complete sequences of 150 new cDNA clones from brain which code
RT   for large proteins in vitro.";
RL   DNA Res. 7:65-73(2000).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-266, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein
RT   phosphorylation analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [7]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-188 AND SER-194, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-188 AND SER-194, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-188; SER-194; THR-198
RP   AND SER-305, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 1-181, AND SUBUNIT.
RX   PubMed=11554796; DOI=10.1006/jmbi.2001.4952;
RA   Schwarz G., Schrader N., Mendel R.R., Hecht H.-J., Schindelin H.;
RT   "Crystal structures of human gephyrin and plant Cnx1 G domains:
RT   comparative analysis and functional implications.";
RL   J. Mol. Biol. 312:405-418(2001).
RN   [15]
RP   VARIANT TYR-10, CHARACTERIZATION OF VARIANT TYR-10, AND INTERACTION
RP   WITH GLRB.
RX   PubMed=12684523; DOI=10.1074/jbc.M301070200;
RA   Rees M.I., Harvey K., Ward H., White J.H., Evans L., Duguid I.C.,
RA   Hsu C.-C., Coleman S.L., Miller J., Baer K., Waldvogel H.J.,
RA   Gibbon F., Smart T.G., Owen M.J., Harvey R.J., Snell R.G.;
RT   "Isoform heterogeneity of the human gephyrin gene (GPHN), binding
RT   domains to the glycine receptor, and mutation analysis in
RT   hyperekplexia.";
RL   J. Biol. Chem. 278:24688-24696(2003).
RN   [16]
RP   VARIANT MOCODC ALA-580, AND PATHWAY.
RX   PubMed=22040219; DOI=10.1111/j.1399-0004.2011.01709.x;
RA   Reiss J., Lenz U., Aquaviva-Bourdain C., Joriot-Chekaf S.,
RA   Mention-Mulliez K., Holder-Espinasse M.;
RT   "A GPHN point mutation leading to molybdenum cofactor deficiency.";
RL   Clin. Genet. 80:598-599(2011).
RN   [17]
RP   VARIANT MOCODC ASP-375, CHARACTERIZATION OF MOCODC VARIANTS ASP-375
RP   AND ALA-580, INTERACTION WITH GABRA3 AND GLRB, SUBCELLULAR LOCATION,
RP   SUBUNIT, FUNCTION, CATALYTIC ACTIVITY, AND PATHWAY.
RX   PubMed=26613940; DOI=10.15252/emmm.201505323;
RG   EuroEPINOMICS Dravet working group;
RA   Dejanovic B., Djemie T., Gruenewald N., Suls A., Kress V., Hetsch F.,
RA   Craiu D., Zemel M., Gormley P., Lal D., Myers C.T., Mefford H.C.,
RA   Palotie A., Helbig I., Meier J.C., De Jonghe P., Weckhuysen S.,
RA   Schwarz G.;
RT   "Simultaneous impairment of neuronal and metabolic function of mutated
RT   gephyrin in a patient with epileptic encephalopathy.";
RL   EMBO Mol. Med. 7:1580-1594(2015).
CC   -!- FUNCTION: Microtubule-associated protein involved in membrane
CC       protein-cytoskeleton interactions. It is thought to anchor the
CC       inhibitory glycine receptor (GLYR) to subsynaptic microtubules.
CC       Catalyzes two steps in the biosynthesis of the molybdenum
CC       cofactor. In the first step, molybdopterin is adenylated.
CC       Subsequently, molybdate is inserted into adenylated molybdopterin
CC       and AMP is released. {ECO:0000269|PubMed:26613940}.
CC   -!- CATALYTIC ACTIVITY: ATP + molybdopterin = diphosphate + adenylyl-
CC       molybdopterin. {ECO:0000305|PubMed:26613940}.
CC   -!- CATALYTIC ACTIVITY: Adenylyl-molybdopterin + molybdate =
CC       molybdenum cofactor + AMP. {ECO:0000305|PubMed:22040219,
CC       ECO:0000305|PubMed:26613940}.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC   -!- ENZYME REGULATION: Inhibited by copper and tungsten.
CC       {ECO:0000250}.
CC   -!- PATHWAY: Cofactor biosynthesis; molybdopterin biosynthesis.
CC       {ECO:0000269|PubMed:11095995, ECO:0000269|PubMed:22040219,
CC       ECO:0000269|PubMed:26613940}.
CC   -!- SUBUNIT: Homotrimer, homodimer and homooligomer (PubMed:26613940).
CC       Interacts with GABARAP (By similarity). Interacts with SRGAP2 (via
CC       SH3 domain) (By similarity). Interacts with GABRA3
CC       (PubMed:26613940). Interacts with GLRB (PubMed:26613940,
CC       PubMed:12684523). GABRA3 and GLRB occupy overlapping binding sites
CC       (By similarity). {ECO:0000250|UniProtKB:Q03555,
CC       ECO:0000250|UniProtKB:Q8BUV3, ECO:0000269|PubMed:12684523,
CC       ECO:0000269|PubMed:26613940}.
CC   -!- INTERACTION:
CC       P63167:DYNLL1; NbExp=2; IntAct=EBI-2371891, EBI-349105;
CC   -!- SUBCELLULAR LOCATION: Cell junction, synapse
CC       {ECO:0000250|UniProtKB:Q03555}. Cell junction, synapse,
CC       postsynaptic cell membrane {ECO:0000269|PubMed:26613940};
CC       Peripheral membrane protein {ECO:0000250|UniProtKB:Q03555};
CC       Cytoplasmic side {ECO:0000250|UniProtKB:Q03555}. Cytoplasm,
CC       cytoskeleton {ECO:0000250|UniProtKB:Q03555}. Cell membrane
CC       {ECO:0000250|UniProtKB:Q03555}; Peripheral membrane protein
CC       {ECO:0000250|UniProtKB:Q03555}; Cytoplasmic side
CC       {ECO:0000250|UniProtKB:Q03555}. Cell projection, dendrite
CC       {ECO:0000269|PubMed:26613940}. Note=Cytoplasmic face of
CC       glycinergic postsynaptic membranes.
CC       {ECO:0000250|UniProtKB:Q03555}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9NQX3-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9NQX3-2; Sequence=VSP_021769;
CC   -!- DISEASE: Molybdenum cofactor deficiency, complementation group C
CC       (MOCODC) [MIM:615501]: A form of molybdenum cofactor deficiency,
CC       an autosomal recessive metabolic disorder leading to the
CC       pleiotropic loss of molybdoenzyme activities. It is clinically
CC       characterized by onset in infancy of poor feeding, intractable
CC       seizures, severe psychomotor retardation, and death in early
CC       childhood in most patients. {ECO:0000269|PubMed:11095995,
CC       ECO:0000269|PubMed:22040219, ECO:0000269|PubMed:26613940}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: In the N-terminal section; belongs to the MoaB/Mog
CC       family. {ECO:0000305}.
CC   -!- SIMILARITY: In the C-terminal section; belongs to the MoeA family.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA92623.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/GPHNID317.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AJ272033; CAC81240.1; -; mRNA.
DR   EMBL; AF272663; AAF81785.1; -; mRNA.
DR   EMBL; AJ272343; CAC10537.1; -; mRNA.
DR   EMBL; AB037806; BAA92623.1; ALT_INIT; mRNA.
DR   EMBL; BC030016; AAH30016.1; -; mRNA.
DR   CCDS; CCDS32103.1; -. [Q9NQX3-1]
DR   CCDS; CCDS9777.1; -. [Q9NQX3-2]
DR   RefSeq; NP_001019389.1; NM_001024218.1. [Q9NQX3-1]
DR   RefSeq; NP_065857.1; NM_020806.4. [Q9NQX3-2]
DR   UniGene; Hs.208765; -.
DR   PDB; 1JLJ; X-ray; 1.60 A; A/B/C=1-181.
DR   PDBsum; 1JLJ; -.
DR   ProteinModelPortal; Q9NQX3; -.
DR   SMR; Q9NQX3; -.
DR   BioGrid; 115537; 30.
DR   DIP; DIP-41076N; -.
DR   IntAct; Q9NQX3; 13.
DR   MINT; MINT-139581; -.
DR   STRING; 9606.ENSP00000417901; -.
DR   DrugBank; DB01942; Formic Acid.
DR   DrugBank; DB03766; Propanoic Acid.
DR   MoonProt; Q9NQX3; -.
DR   iPTMnet; Q9NQX3; -.
DR   PhosphoSitePlus; Q9NQX3; -.
DR   BioMuta; GPHN; -.
DR   DMDM; 13431554; -.
DR   EPD; Q9NQX3; -.
DR   MaxQB; Q9NQX3; -.
DR   PaxDb; Q9NQX3; -.
DR   PeptideAtlas; Q9NQX3; -.
DR   PRIDE; Q9NQX3; -.
DR   DNASU; 10243; -.
DR   Ensembl; ENST00000315266; ENSP00000312771; ENSG00000171723. [Q9NQX3-1]
DR   Ensembl; ENST00000478722; ENSP00000417901; ENSG00000171723. [Q9NQX3-2]
DR   GeneID; 10243; -.
DR   KEGG; hsa:10243; -.
DR   UCSC; uc001xix.4; human. [Q9NQX3-1]
DR   CTD; 10243; -.
DR   DisGeNET; 10243; -.
DR   GeneCards; GPHN; -.
DR   GeneReviews; GPHN; -.
DR   HGNC; HGNC:15465; GPHN.
DR   HPA; CAB004419; -.
DR   HPA; HPA003116; -.
DR   HPA; HPA024694; -.
DR   MalaCards; GPHN; -.
DR   MIM; 603930; gene.
DR   MIM; 615501; phenotype.
DR   neXtProt; NX_Q9NQX3; -.
DR   OpenTargets; ENSG00000171723; -.
DR   Orphanet; 3197; Hereditary hyperekplexia.
DR   Orphanet; 308400; Sulfite oxidase deficiency due to molybdenum cofactor deficiency type C.
DR   PharmGKB; PA28840; -.
DR   eggNOG; KOG2371; Eukaryota.
DR   eggNOG; COG0303; LUCA.
DR   eggNOG; COG0521; LUCA.
DR   GeneTree; ENSGT00390000016577; -.
DR   HOGENOM; HOG000280651; -.
DR   HOVERGEN; HBG005828; -.
DR   InParanoid; Q9NQX3; -.
DR   KO; K15376; -.
DR   PhylomeDB; Q9NQX3; -.
DR   TreeFam; TF300902; -.
DR   BioCyc; MetaCyc:ENSG00000171723-MONOMER; -.
DR   Reactome; R-HSA-947581; Molybdenum cofactor biosynthesis.
DR   SIGNOR; Q9NQX3; -.
DR   UniPathway; UPA00344; -.
DR   ChiTaRS; GPHN; human.
DR   EvolutionaryTrace; Q9NQX3; -.
DR   GeneWiki; GPHN; -.
DR   GenomeRNAi; 10243; -.
DR   PRO; PR:Q9NQX3; -.
DR   Proteomes; UP000005640; Chromosome 14.
DR   Bgee; ENSG00000171723; -.
DR   CleanEx; HS_GPHN; -.
DR   ExpressionAtlas; Q9NQX3; baseline and differential.
DR   Genevisible; Q9NQX3; HS.
DR   GO; GO:0030054; C:cell junction; IEA:UniProtKB-KW.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005856; C:cytoskeleton; IEA:UniProtKB-SubCell.
DR   GO; GO:0030425; C:dendrite; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0045211; C:postsynaptic membrane; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0061598; F:molybdopterin adenylyltransferase activity; IBA:GO_Central.
DR   GO; GO:0043546; F:molybdopterin cofactor binding; IDA:CAFA.
DR   GO; GO:0061599; F:molybdopterin molybdotransferase activity; IBA:GO_Central.
DR   GO; GO:0008940; F:nitrate reductase activity; IMP:CAFA.
DR   GO; GO:0097112; P:gamma-aminobutyric acid receptor clustering; IDA:UniProtKB.
DR   GO; GO:0072579; P:glycine receptor clustering; IBA:GO_Central.
DR   GO; GO:0006777; P:Mo-molybdopterin cofactor biosynthetic process; IBA:GO_Central.
DR   GO; GO:0018315; P:molybdenum incorporation into molybdenum-molybdopterin complex; IBA:GO_Central.
DR   GO; GO:0032324; P:molybdopterin cofactor biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0010038; P:response to metal ion; IMP:CAFA.
DR   CDD; cd00886; MogA_MoaB; 1.
DR   Gene3D; 2.40.340.10; -; 1.
DR   Gene3D; 3.40.980.10; -; 2.
DR   InterPro; IPR001453; MoaB/Mog_dom.
DR   InterPro; IPR008284; MoCF_biosynth_CS.
DR   InterPro; IPR005111; MoeA_C_domain_IV.
DR   InterPro; IPR005110; MoeA_linker/N.
DR   Pfam; PF00994; MoCF_biosynth; 2.
DR   Pfam; PF03454; MoeA_C; 1.
DR   Pfam; PF03453; MoeA_N; 1.
DR   SMART; SM00852; MoCF_biosynth; 2.
DR   SUPFAM; SSF53218; SSF53218; 2.
DR   SUPFAM; SSF63867; SSF63867; 1.
DR   SUPFAM; SSF63882; SSF63882; 1.
DR   TIGRFAMs; TIGR00177; molyb_syn; 2.
DR   PROSITE; PS01078; MOCF_BIOSYNTHESIS_1; 1.
DR   PROSITE; PS01079; MOCF_BIOSYNTHESIS_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell junction;
KW   Cell membrane; Cell projection; Complete proteome; Cytoplasm;
KW   Cytoskeleton; Disease mutation; Magnesium; Membrane; Metal-binding;
KW   Molybdenum; Molybdenum cofactor biosynthesis; Multifunctional enzyme;
KW   Nucleotide-binding; Phosphoprotein; Polymorphism;
KW   Postsynaptic cell membrane; Reference proteome; Synapse; Transferase.
FT   CHAIN         1    736       Gephyrin.
FT                                /FTId=PRO_0000170964.
FT   REGION       14    166       MPT Mo-transferase.
FT   REGION      140    316       Interaction with GABARAP. {ECO:0000250}.
FT   REGION      326    736       MPT adenylyltransferase.
FT   MOD_RES     188    188       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     194    194       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     198    198       Phosphothreonine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     200    200       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q8BUV3}.
FT   MOD_RES     262    262       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q8BUV3}.
FT   MOD_RES     265    265       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:Q8BUV3}.
FT   MOD_RES     266    266       Phosphothreonine.
FT                                {ECO:0000244|PubMed:16964243}.
FT   MOD_RES     268    268       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q8BUV3}.
FT   MOD_RES     270    270       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q8BUV3}.
FT   MOD_RES     305    305       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   VAR_SEQ     243    243       K -> KKHPFYTSPAVVMAHGEQPIPGLINYSHHSTDER
FT                                (in isoform 2).
FT                                {ECO:0000303|PubMed:11418245,
FT                                ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_021769.
FT   VARIANT      10     10       N -> Y (found in a patient with
FT                                hyperekplexia; unknown pathological
FT                                significance; does not disrupt GLRB-GPHN
FT                                interactions; does not affect the
FT                                structural lattices formed by GPHN;
FT                                dbSNP:rs121908539).
FT                                {ECO:0000269|PubMed:12684523}.
FT                                /FTId=VAR_044162.
FT   VARIANT     375    375       G -> D (in MOCODC; patient phenotype
FT                                resembling Dravet syndrome; abolishes
FT                                postsynaptic clustering of GPHN;
FT                                decreases cell-surface expression of GABA
FT                                receptors; impairs postsynaptic currents;
FT                                catalytically inactive; decreases binding
FT                                affinity toward GABRA3; decreases binding
FT                                affinity toward GLRB).
FT                                {ECO:0000269|PubMed:26613940}.
FT                                /FTId=VAR_075626.
FT   VARIANT     580    580       D -> A (in MOCODC; lacks molybdenum
FT                                cofactor synthesis activity;
FT                                dbSNP:rs397518420).
FT                                {ECO:0000269|PubMed:22040219,
FT                                ECO:0000269|PubMed:26613940}.
FT                                /FTId=VAR_070275.
FT   CONFLICT    261    261       A -> V (in Ref. 1; CAC81240).
FT                                {ECO:0000305}.
FT   STRAND       16     22       {ECO:0000244|PDB:1JLJ}.
FT   HELIX        24     27       {ECO:0000244|PDB:1JLJ}.
FT   HELIX        34     44       {ECO:0000244|PDB:1JLJ}.
FT   TURN         46     49       {ECO:0000244|PDB:1JLJ}.
FT   STRAND       52     59       {ECO:0000244|PDB:1JLJ}.
FT   HELIX        63     75       {ECO:0000244|PDB:1JLJ}.
FT   STRAND       80     86       {ECO:0000244|PDB:1JLJ}.
FT   STRAND       89     91       {ECO:0000244|PDB:1JLJ}.
FT   HELIX        96    103       {ECO:0000244|PDB:1JLJ}.
FT   STRAND      105    107       {ECO:0000244|PDB:1JLJ}.
FT   HELIX       109    122       {ECO:0000244|PDB:1JLJ}.
FT   HELIX       124    128       {ECO:0000244|PDB:1JLJ}.
FT   STRAND      133    136       {ECO:0000244|PDB:1JLJ}.
FT   STRAND      139    144       {ECO:0000244|PDB:1JLJ}.
FT   HELIX       148    158       {ECO:0000244|PDB:1JLJ}.
FT   HELIX       159    161       {ECO:0000244|PDB:1JLJ}.
FT   HELIX       162    169       {ECO:0000244|PDB:1JLJ}.
FT   HELIX       175    178       {ECO:0000244|PDB:1JLJ}.
SQ   SEQUENCE   736 AA;  79748 MW;  E2BDA3AD3AB962C0 CRC64;
     MATEGMILTN HDHQIRVGVL TVSDSCFRNL AEDRSGINLK DLVQDPSLLG GTISAYKIVP
     DEIEEIKETL IDWCDEKELN LILTTGGTGF APRDVTPEAT KEVIEREAPG MALAMLMGSL
     NVTPLGMLSR PVCGIRGKTL IINLPGSKKG SQECFQFILP ALPHAIDLLR DAIVKVKEVH
     DELEDLPSPP PPLSPPPTTS PHKQTEDKGV QCEEEEEEKK DSGVASTEDS SSSHITAAAI
     AAKIPDSIIS RGVQVLPRDT ASLSTTPSES PRAQATSRLS TASCPTPKVQ SRCSSKENIL
     RASHSAVDIT KVARRHRMSP FPLTSMDKAF ITVLEMTPVL GTEIINYRDG MGRVLAQDVY
     AKDNLPPFPA SVKDGYAVRA ADGPGDRFII GESQAGEQPT QTVMPGQVMR VTTGAPIPCG
     ADAVVQVEDT ELIRESDDGT EELEVRILVQ ARPGQDIRPI GHDIKRGECV LAKGTHMGPS
     EIGLLATVGV TEVEVNKFPV VAVMSTGNEL LNPEDDLLPG KIRDSNRSTL LATIQEHGYP
     TINLGIVGDN PDDLLNALNE GISRADVIIT SGGVSMGEKD YLKQVLDIDL HAQIHFGRVF
     MKPGLPTTFA TLDIDGVRKI IFALPGNPVS AVVTCNLFVV PALRKMQGIL DPRPTIIKAR
     LSCDVKLDPR PEYHRCILTW HHQEPLPWAQ STGNQMSSRL MSMRSANGLL MLPPKTEQYV
     ELHKGEVVDV MVIGRL
//
